OTX-TIC, a hydrogel-based implant that delivers travoprost, demonstrated similar IOP control compared with topical therapy, according to a study.
In his presentation at the virtual Association for Research in Vision and Ophthalmology meeting, Damien Goldberg, MD, said that issues including poor adherence to drop therapy affect IOP control in patients with glaucoma.
“[OTX-TIC] demonstrates a new device that can provide a microparticle hydrogel with travoprost with a goal of sustaining drug delivery into the eye for 4 to 6 months so that eye drops won’t be necessary,” he said.